Actively Recruiting
Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective Study
Led by The Affiliated Hospital of Xuzhou Medical University · Updated on 2024-10-01
80
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Our three-step screening system uses commonly used clinical and laboratory parameters to effectively identify patients who may be at high risk of HLH, conduct etiology screening early for patients who meet the diagnostic criteria for HLH, and guide standardized treatment. Therefore, this study proposes to establish a highly accurate and convenient hemophagocytic early warning system to improve the early diagnosis of patients with hemophagocytic syndrome and identify suspected HLH patients early. Etiology screening is performed on patients who meet the diagnostic criteria for HLH, high-risk predisposing factors are identified, and precise treatment is guided, thereby improving the success rate of patient treatment and improving the quality of life.
CONDITIONS
Official Title
Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who meet the first step screening plus have three or more abnormal indicators in the second step
- Patients who meet the first step screening plus have two abnormal indicators in the second step and have high-risk factors for HLH such as lymphoma history, Epstein-Barr virus infection, or autoimmune diseases
You will not qualify if you...
- Patients with liver cirrhosis, liver cancer, or hepatic encephalopathy
- Patients with trauma, hepatosplenic rupture, or other organ hemorrhage
- Patients with severe diseases such as shock, sepsis, or multiple organ failure
- Patients with disseminated intravascular coagulation (DIC)
- Patients with long-term anemia
- Patients with acute promyelocytic leukemia
- Patients with idiopathic deafness
- Patients who have taken hormones or immunosuppressants within 72 hours before admission
- Patients with hereditary fibrinogen deficiency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Affilitated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China, 221006
Actively Recruiting
Research Team
W
Wei Sang, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here